Navigation Links
Antioxidant shown to reduce blindness risk in extremely premature babies
Date:6/14/2012

BOSTON, MARetinopathy of prematurity (ROP) is the second most common cause of childhood blindness in the United States, occurring in half of premature infants born earlier than or at 28 weeks gestational age. The condition is caused by abnormal blood vessel development in the retina of the eye. ROP risk increases with decreasing gestational age.

A study by researchers at Brigham and Women's Hospital (BWH) suggests that the antioxidant, rhSOD (recombinant human Cu/Zn superoxide dismutase), reduces the risk of developing ROP in extremely low gestational age newborns.

The post-hoc analysis study will be published online on June 15, 2012 in Neonatology.

Researchers looked at a subset of data from a previous multicenter trial that randomized 302 preterm infants to receive either rhSOD or placebo for prevention of bronchopulmonary dysplasia (a chronic lung condition that affects newborn babies). Researchers analyzed the data looking specifically at the incidence and severity of ROP in extremely low gestational age newborns.

Within the entire cohort, there were no significant differences in ROP in newborns given placebo versus those given rhSOD. However, those born earlier than 26 weeks (72 babies) had a 22 percent reduction in ROP. The abnormality was reduced by 53 percent for babies born earlier than 25 weeks (24 babies).

"Even though strides have been made in developing interventions to stop ROP from progressing to blindness, there are currently no therapies available for ROP prevention," said Richard Parad, MD, BWH Department of Newborn Medicine, lead study author. "There is a large need for the preventive approach that rhSOD could potentially provide."

The researchers note that while looking at ROP was not the primary outcome for which the prior study was designed, this post-hoc analysis was carefully re-focused on the tiniest babies with the highest ROP risk based on recent advances in the understanding of how ROP develops and on evidence from prior studies of other antioxidants that suggested such agents might interfere with development of ROP.

In light of the findings, the researchers stress that further studies are required to confirm their observations.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related biology news :

1. Antioxidant may disrupt Alzheimers disease process
2. Vitamin D with calcium shown to reduce mortality in elderly
3. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
4. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
5. Leading childhood asthma group supports federal asthma action plan to reduce disparities
6. Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use
7. Drugs from lizard saliva reduces the cravings for food
8. Increasing predator-friendly land can help farmers reduce costs
9. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
10. Hot sauce ingredient reduces beer belly fat as a weight-loss surgery alternative
11. CUNY Energy Institute battery system could reduce buildings electric bills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: